An Effective Epigenetic-PARP inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA-mutations

PURPOSE: Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are primarily effective against BRCA1/2-mutated breast and ovarian cancers but resistance due to reversion of mutated BRCA1/2 and other mechanisms is common. Based on previous reports demonstrating a functional role for DNMT1 in DNA rep...

詳細記述

保存先:
書誌詳細
出版年:Clin Cancer Res
主要な著者: Pulliam, Nicholas, Fang, Fang, Ozes, Ali R., Tang, Jessica, Adewuyi, Adeoluwa, Keer, Harold, Lyons, John, Baylin, Stephen B., Matei, Daniela, Nakshatri, Harikrishna, Rassool, Feyruz V., Miller, Kathy D., Nephew, Kenneth P.
フォーマット: Artigo
言語:Inglês
出版事項: 2018
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7003715/
https://ncbi.nlm.nih.gov/pubmed/29615458
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-0204
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料